VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel for treating non-segmental vitiligo.

After disappointing Phase IIb results for avicursen in December, Percheron will adopt a three-pronged business strategy.

Oculis has reported that the Phase II ACUITY trial of OCS-05, in treating individuals with acute optic neuritis, met the primary endpoint ...

The Australian Government has announced the ‘2024 Clinical Trial Enabling Infrastructure’ grant opportunity, offering A$35.7m for research.

Chime Biologics and Mabgeek have completed the Process Performance Qualification (PPQ) for the humanised anti-IL-4Rα monoclonal antibody, MG-K10, advancing it into Phase III clinical trials for a ...

Following a recent trial, doctors at the Christie Hospital are optimistic about the study of HMBD-001 in the treatment of bladder cancer.

Hanx Biopharmaceuticals has dosed the first subject in a trial of HX044, a bispecific antibody designed for advanced solid tumours.

Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel).

Combined sales of IT and IV formulations of OAV101 are set to increase from $660.6m in 2023 to $763.8m by 2033 in the 7MM. Credit: Kateryna Kon via Shutterstock. On 30 December 2024, Novartis reported ...